I'm LongbridgeAI, I can summarize articles.Karyopharm Therapeutics (KPTI.US) fell nearly 14% in premarket trading to a record low of $0.0346.
Nasdaq notified the company that it will be delisted, with trading suspended on Nov. 11.
Karyopharm Therapeutics filed for Chapter 11 bankruptcy protection on Nov. 2, 2026, under which existing equity is expected to be canceled. The company is seeking a $110 million debtor-in-possession financing facility and announced a planned merger with Ayrmid Ltd. as part of its restructuring. The transaction includes up to $55 million in DIP financing and is expected to close in the first quarter of 2027.
Based on public media reports. AI-generated; not investment advice.